NO20054072L - Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist. - Google Patents

Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist.

Info

Publication number
NO20054072L
NO20054072L NO20054072A NO20054072A NO20054072L NO 20054072 L NO20054072 L NO 20054072L NO 20054072 A NO20054072 A NO 20054072A NO 20054072 A NO20054072 A NO 20054072A NO 20054072 L NO20054072 L NO 20054072L
Authority
NO
Norway
Prior art keywords
antagonist
therapeutic agent
spinal cord
cord injury
interleukin
Prior art date
Application number
NO20054072A
Other languages
English (en)
Other versions
NO20054072D0 (no
Inventor
Hideyuki Okano
Seiji Okada
Masaya Nakamura
Kazuyuki Yoshizaki
Original Assignee
Univ Keio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Keio filed Critical Univ Keio
Publication of NO20054072D0 publication Critical patent/NO20054072D0/no
Publication of NO20054072L publication Critical patent/NO20054072L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

2005-10-25 Sammendrag Et terapeutisk middel for ryggmargsskade, en modulator for differensiering av nevrale stamceller og en hemmer av differensiering til gliaceller omfattende en interieukin-6 antagonist som en aktiv bestanddel.
NO20054072A 2003-02-24 2005-09-01 Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist. NO20054072L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003046214 2003-02-24
PCT/JP2004/002111 WO2004073741A1 (ja) 2003-02-24 2004-02-24 インターロイキン－６アンタゴニストを含有する脊髄損傷治療剤

Publications (2)

Publication Number Publication Date
NO20054072D0 NO20054072D0 (no) 2005-09-01
NO20054072L true NO20054072L (no) 2005-10-25

Family

ID=32905544

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054072A NO20054072L (no) 2003-02-24 2005-09-01 Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist.

Country Status (17)

Country Link
US (1) US20060165696A1 (no)
EP (1) EP1607100A4 (no)
JP (1) JP4555924B2 (no)
KR (1) KR101142624B1 (no)
CN (2) CN100340294C (no)
AU (1) AU2004212843B2 (no)
BR (1) BRPI0407747A (no)
CA (1) CA2516945A1 (no)
HK (1) HK1088230A1 (no)
HR (1) HRP20050837A2 (no)
IL (3) IL170399A (no)
MX (1) MXPA05008713A (no)
NO (1) NO20054072L (no)
NZ (1) NZ541928A (no)
PL (1) PL378199A1 (no)
RU (2) RU2358761C2 (no)
WO (1) WO2004073741A1 (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0983767B1 (en) 1997-03-21 2008-09-10 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for the treatment of multiple sclerosis containing antagonist anti-IL-6-receptor antibodies
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP3578168A1 (en) 2002-02-14 2019-12-11 Chugai Seiyaku Kabushiki Kaisha Formulation of antibody-containing solutions comprising a sugar as a stabilizer
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP3269738A1 (en) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
EP1941908B1 (en) * 2005-10-21 2015-08-19 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for heart disease
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) * 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
US20080015465A1 (en) * 2006-06-15 2008-01-17 Scuderi Gaetano J Methods for diagnosing and treating pain in the spinal cord
US7919095B2 (en) * 2006-08-03 2011-04-05 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies
PE20081635A1 (es) 2007-01-23 2009-01-07 Chugai Pharmaceutical Co Ltd Agentes para suprimir la reaccion de rechazo cronica
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
TWI609965B (zh) * 2007-05-21 2018-01-01 艾爾德生物控股有限責任公司 新穎兔抗體人化方法以及經人化之兔抗體
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
NZ597767A (en) 2007-05-21 2013-06-28 Bristol Myers Squibb Co Antibodies to IL-6 and use thereof
US7709215B2 (en) * 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
JP2011520898A (ja) 2008-05-13 2011-07-21 ノビミューン エスアー 抗ｉｌ−６／ｉｌ−６ｒ抗体およびそれらの使用方法
TWI528973B (zh) * 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
CN102740888B (zh) 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
ES2932398T3 (es) 2010-05-28 2023-01-18 Chugai Pharmaceutical Co Ltd Potenciador de la respuesta de las células T antitumorales
TWI603738B (zh) 2010-11-08 2017-11-01 建南德克公司 皮下投予抗－ｉｌ－６受體抗體
ES2847891T3 (es) 2010-11-23 2021-08-04 Vitaeris Inc Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
CA2827581A1 (en) 2011-03-03 2012-09-07 Apexigen, Inc. Anti-il-6 receptor antibodies and methods of use
JP6563910B2 (ja) 2013-07-04 2019-08-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
AU2018234844B2 (en) 2017-03-17 2024-01-25 Ohio State Innovation Foundation Nanoparticles for delivery of chemopreventive agents
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
KR20220064039A (ko) 2020-11-11 2022-05-18 정성삼 척수 손상 예방 또는 치료용 조성물
KR102320780B1 (ko) 2021-01-29 2021-11-02 정성삼 척추 통증 완화 및 척추 유연성 개선을 위한 조성물 및 이의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US521628A (en) 1894-06-19 Housekeeping-cabinet
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 ｇｐ１３０蛋白質に対する抗体
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
IT1274350B (it) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
IT1274782B (it) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
EP0811384B1 (en) * 1995-02-13 2006-06-21 Chugai Seiyaku Kabushiki Kaisha Muscle protein decomposition inhibitor containing il-6 receptor antibody
FR2733250B1 (fr) 1995-04-21 1997-07-04 Diaclone Anticorps monoclonaux anti-gp130, et leurs utilisations
US5571513A (en) 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
CA2307826A1 (en) * 1997-10-27 1999-05-06 Creative Biomolecules, Inc. Enhancement of morphogen activity
AU2672099A (en) * 1998-02-13 1999-08-30 Wistar Institute, The Compositions and methods for wound healing
US6419944B2 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders

Also Published As

Publication number Publication date
EP1607100A1 (en) 2005-12-21
IL205618A (en) 2012-02-29
WO2004073741A8 (ja) 2005-04-07
US20060165696A1 (en) 2006-07-27
KR101142624B1 (ko) 2012-06-15
KR20060006004A (ko) 2006-01-18
RU2358761C2 (ru) 2009-06-20
CN101130077A (zh) 2008-02-27
AU2004212843B2 (en) 2009-06-25
RU2009102845A (ru) 2010-08-10
AU2004212843A1 (en) 2004-09-02
PL378199A1 (pl) 2006-03-06
BRPI0407747A (pt) 2006-02-14
EP1607100A4 (en) 2007-06-13
NO20054072D0 (no) 2005-09-01
MXPA05008713A (es) 2005-09-20
CN100340294C (zh) 2007-10-03
IL200098A (en) 2012-10-31
CA2516945A1 (en) 2004-09-02
JP4555924B2 (ja) 2010-10-06
HRP20050837A2 (en) 2005-12-31
WO2004073741A1 (ja) 2004-09-02
NZ541928A (en) 2009-06-26
HK1088230A1 (en) 2006-11-03
RU2005130011A (ru) 2006-02-10
IL170399A (en) 2011-02-28
CN1753694A (zh) 2006-03-29
JPWO2004073741A1 (ja) 2007-08-23

Similar Documents

Publication Publication Date Title
NO20054072L (no) Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist.
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
ATE427747T1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
EP2329842A3 (en) Interleukin-1 inhibitors in the treatment of diseases
DK1478399T3 (da) Oral dosisform indeholdende en pde-4-inhibitor som en aktiv bestanddel og polyvinylpyrrolidone som excipiens
DK1364946T3 (da) Isoxazolin-derivat og herbicid omfattende samme som aktiv bestanddel
NO20083324L (no) Multisykliske aminosyrederivater og anvendelse derav
NO20064127L (no) Terapeutisk middel for Auris interna forstyrrelse, inneholdende IL-6 antagonist som aktiv bestanddel
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
ATE386034T1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
DE602005024704D1 (de) Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
DK1334731T3 (da) Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel
NO20074697L (no) Ikke-aromatisk, nitrogenholdig heterosyklisk-1-karboksylatester-pyridylderivat
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
NO20062150L (no) Nye ketooksadiazolderivater som katepsinhibitorer
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
DK1585743T3 (da) 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
NO20080035L (no) Benzooksazol-2-on derivater som lipase og fosfolipaseinhibitorer
TW200507829A (en) New combination
HRP20031057B1 (hr) Tableta koja sadrži cetirizin i pseudoefedrin
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
TW200505408A (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application